- Loperamide hydrochloride
-
- $425.00 / 10kilograms
-
2024-04-18
- CAS:34552-83-5
- Min. Order: 10kilograms
- Purity: 99%
- Supply Ability: 100tons
- Loperamide hydrochloride
-
- $1.00 / 1mg
-
2024-04-15
- CAS:34552-83-5
- Min. Order: 100mg
- Purity: 98.0%
- Supply Ability: 5ton/month
|
| | Loperamide hydrochloride Basic information |
| | Loperamide hydrochloride Chemical Properties |
| Melting point | 223-225°C | | density | 1.1905 (rough estimate) | | refractive index | 1.6100 (estimate) | | storage temp. | 2-8°C | | solubility | Slightly soluble in water, freely soluble in ethanol (96 per cent) and in methanol. | | pka | 8.66(at 25℃) | | color | White to Almost white | | Merck | 14,5571 | | CAS DataBase Reference | 34552-83-5(CAS DataBase Reference) |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | RTECS | TM4960000 | | HazardClass | 6.1(b) | | PackingGroup | III | | HS Code | 29333990 | | Toxicity | LD50 in mice (mg/kg): 75 s.c.; 28 i.p.; 105 orally; in rats (mg/kg): 185 orally (Niemegeers) |
| | Loperamide hydrochloride Usage And Synthesis |
| Chemical Properties | White Solid | | Originator | Imodium,Janssen,UK,1975 | | Uses | Ca channel blocker | | Uses | Labeled Loperamide, which is used as an antidiarrheal | | Uses | Loperamide hydrochloride is a Ca2+ channel protein inhibitor and MOR activator. | | Indications | Loperamide hydrochloride (Imodium) structurally
resembles both haloperidol and meperidine. In equal
doses, loperamide protects against diarrhea longer than
does diphenoxylate. It reduces the daily fecal volume
and decreases intestinal fluid and electrolyte loss.
Loperamide produces rapid and sustained inhibition of
the peristaltic reflex through depression of longitudinal
and circular muscle activity.The drug also possesses antisecretory
activity, presumably through an effect on intestinal
opioid receptors. | | Definition | ChEBI: A hydrochloride obtained by combining loperamide with one equivalent of hydrochloric acid. Used for treatment of diarrhoea resulting from gastroenteritis or inflammatory bowel disease. | | Manufacturing Process | 23.6 parts of 2-oxo-3,3-diphenyl-tetrahydrofuranare melted at 100°C in an
oil-bath and gaseous hydrogen bromide is introduced into it during 3 hours.
The reaction mixture is cooled and triturated in benzene. The product is
filtered off, washed with petroleum ether and dried in an exsiccator, yielding
4-bromo-2,2-diphenylbutyric acid; MP 127.5%.
To a stirred suspension of 16 parts of 4-bromo-2,2-diphenylbutyric acid in 150
parts of chloroform are added dropwise 16 parts of thionyl chloride and the
whole is stirred and refluxed for 2 hours. The reaction mixture is evaporated,yielding 4-bromo-2,2-diphenyl-butyrylchloride as a residue.
60 parts of 4-bromo-2,2-diphenylbutyrylchloride are dissolved in 400 parts of
toluene and gaseous dimethylamine is introduced slowly into the solution
while cooling (temperature is kept at about 0°C). The introduction is ceased
when dimethylamine escapes from the cooler, and stirring is continued for 2
hours at ordinary temperature. The precipitated product is filtered off and
dissolved in a minimum quantity of water. The product is extracted with
chloroform. The extract is dried and evaporated. The residue solidifies on
triturating in 4-methyl-2-pentanone. The solid is filtered off and dried, yielding
dimethyl -(tetrahydro-3,3-diphenyl-2-furylidene)ammonium bromide; MP 169°
to 171.5°C.
A mixture of 6.33 parts of 4-(p-chlorophenyl)-4-piperidinol, 8 parts of sodium
carbonate, 0.2 part of potassium iodide and 240 parts of 4-methyl-2-
pentanone is distilled azeotropically. Then there are added 12.12 parts of
dimethyl-(tetrahydro-3,3-diphenyl-2-furylidene)ammonium bromide (from the
preceding step) and the whole is stirred and refluxed for about 15 hours. The
reaction mixture is filtered hot and the filtrate is evaporated.
The oily residue is dissolved in 2-propanol and to this solution is added an
excess of 2-propanol previously saturated with gaseous hydrogen chloride.
The whole is evaporated and the oily residue is warmed in diluted hydrochloric
acid solution. Upon the addition of toluene, the salt is precipitated. It is
filtered off, boiled in acetone, and filtered off again after cooling, yielding 4-
(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenylpiperidine-1-butyramide
hydrochloride; MP 222.1°C. | | Brand name | Imodium (Janssen);
Imodium (McNeil). | | Therapeutic Function | Antidiarrheal | | General Description | Loperamide is an antidiarrheal agent used in controlling acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel diseases. | | Biological Activity | High affinity μ -opioid receptor agonist with peripheral selectivity (K i values are 2, 48 and 1156 nM for μ -, δ - and κ -opioid receptors respectively). Antidiarrhoeal and antihyperalgesic agent. Also a Ca 2+ channel blocker; at low micromolar concentrations it blocks broad spectrum neuronal HVA Ca 2+ channels and at higher concentrations it reduces Ca 2+ flux through NMDA receptor operated channels. | | Biochem/physiol Actions | Loperamide hydrochloride (HCl) is a non-selective Ca2+ channel blocker. At nanomolar concentrations, it binds to μ-opioid receptors. Loperamide HCl does not cross the blood-brain barrier. | | Mechanism of action | Loperamide also is a potent inhibitor of intestinal CYP3A4, increasing the intestinal absorption of
other CYP3A4 substrates. The clinically significant drug interactions of loperamide with
coadministered CYP3A4 and CYP2C8 substrates or inhibitors would be limited, however, because
of its two metabolic pathways. | | Pharmacokinetics | Loperamide is
marketed as capsules (2 mg) and liquid (1 mg/5 mL) preparations. The recommended dose is 4 mg
initially and an additional 2 mg following each diarrheal stool. The dose should not exceed 16
mg/day. It is too lipophilic to dissolve in water for an intravenous dosage form, a property that limits
its abuse potential. The compound is highly lipophilic and undergoes slow dissolution, thus limiting
the bioavailability of the agent to approximately 40% of the dose. Its low oral bioavailability also
can be attributed to first-pass metabolism by both CYP2C8 and CYP3A4 to its primary N-demethyl
metabolite. Peak plasma levels are reached in approximately 5 hours, with an elimination half-life
of approximately 11 hours. Approximately 1% of the dose is excreted into the urine unchanged. | | Clinical Use | Loperamide is effective
against a wide range of secretory stimuli and can be
used in the control and symptomatic relief of acute diarrhea
that is not secondary to bacterial infection. | | Side effects | Adverse effects associated with its use include abdominal
pain and distention, constipation, dry mouth, hypersensitivity,
and nausea and vomiting. | | storage | Room temperature |
| | Loperamide hydrochloride Preparation Products And Raw materials |
|